State University are reporting for the first
time that nanoparticles 1/5,000 the diameter of a human hair encapsulating an
experimental anticancer agent, kill human melanoma and drug-resistant breast
cancer cells growing in laboratory cultures. The discovery could lead to the
development of a new generation of anti-cancer drugs that are safer and more
effective than conventional chemotherapy agents, the scientists suggest. The
research is scheduled for the Dec. 10 issue of ACS’ Nano Letters, a monthly journal.
the new study, Mark Kester, James Adair and colleagues at Penn State's
Hershey Medical Center and University Park campus point out that certain
nanoparticles have shown promise as drug delivery vehicles. However, many of
these particles will not dissolve in body fluids and are toxic to cells, making
them unsuitable for drug delivery in humans. Although promising as an
anti-cancer agent, ceramide also is insoluble in the blood stream, making
delivery to cancer cells difficult.
scientists report a potential solution with development of calcium phosphate
nanocomposite particles (CPNPs). The particles are soluble and with ceramide
encapsulated with the calcium phosphate, effectively make ceramide soluble.
With ceramide encapsulated inside, the CPNPs killed 95 percent of human melanoma
cells and was “highly effective” against human breast cancer cells that are
normally resistant to anticancer drugs, the researchers say.
State Research Foundation has licensed the calcium phosphate nanocomposite
particle technology known as "NanoJackets" to Keystone Nano, Inc. MK and JA are
CMO and CSO, respectively.
-- An American Chemical Society (ACS) News Release on December 10, 2008.